Literature DB >> 23817924

Relationship between 13C-aminopyrine breath test and the MELD score and its long-term prognostic use in patients with cirrhosis.

Edoardo G Giannini1, Vincenzo Savarino.   

Abstract

BACKGROUND: (13)C-Aminopyrine breath test ((13)C-ABT) is a non-invasive, dynamic, quantitative liver function test, and the model for end-stage liver disease (MELD) is a recognised biochemical score used to predict survival in patients with cirrhosis. AIMS: The purpose of this study was to evaluate the relationship between the (13)C-ABT and MELD score in a cohort of cirrhotic patients and, moreover, to assess the prognostic value of (13)C-ABT results in the same group of patients. PATIENTS AND METHODS: Forty-six patients with cirrhosis and without hepatocellular carcinoma who underwent (13)C-ABT and who had at least 1-year follow-up were prospectively included in this study. MELD score was calculated at entry into the study in all patients. End-points of the study were 1-year liver-related death or liver transplantation.
RESULTS: (13)C-ABT %dose/h at 30 min (%dose/h30) results showed significant, inverse correlation with MELD scores (r = -0.414, P = 0.004). During 1-year follow-up nine patients died (19.6 %) and two were transplanted (4.3 %). Median (13)C-ABT %dose/h30 results (3.2 vs. 1.8) were significantly higher in patients who survived as compared to those who died or underwent transplantation (P = 0.04). Receiver operating characteristics curves showed that a (13)C-ABT %dose/h30 cut-off of 2.0 had the best accuracy (c-index = 0.717) in assessing 1-year prognosis.
CONCLUSIONS: We observed a correlation between a flow-independent quantitative liver function test and the MELD score, and found that the (13)C-ABT may accurately provide long-term prognostic information in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817924     DOI: 10.1007/s10620-013-2739-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Temporal trends in early clinical outcomes and health care resource utilization for liver transplantation in the United States.

Authors:  John E Scarborough; Ricardo Pietrobon; Carlos E Marroquin; Janet E Tuttle-Newhall; Paul C Kuo; Bradley H Collins; Dev M Desai; Theodore N Pappas
Journal:  J Gastrointest Surg       Date:  2007-01       Impact factor: 3.452

2.  MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.

Authors:  F Botta; E Giannini; P Romagnoli; A Fasoli; F Malfatti; B Chiarbonello; E Testa; D Risso; G Colla; R Testa
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 3.  Clinical utility of 13C-liver-function breath tests for assessment of hepatic function.

Authors:  P Afolabi; M Wright; S A Wootton; A A Jackson
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

Review 4.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

5.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

Authors:  G B Haycock; G J Schwartz; D H Wisotsky
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

6.  Factors influencing survival at one year in patients with nonbiliary hepatic parenchymal cirrhosis.

Authors:  M Adler; J Van Laethem; A Glibert; M Gelin; N Bourgeois; P Vereerstraeten; M Cremer
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

7.  Aminopyrine breath test predicts surgical risk for patients with liver disease.

Authors:  R A Gill; M W Goodman; G R Golfus; G R Onstad; M P Bubrick
Journal:  Ann Surg       Date:  1983-12       Impact factor: 12.969

8.  [14C]Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis.

Authors:  D A Henry; G Kitchingman; M J Langman
Journal:  Dig Dis Sci       Date:  1985-09       Impact factor: 3.199

9.  Prognostic value of the aminopyrine breath test in cirrhotic patients.

Authors:  J P Villeneuve; C Infante-Rivard; M Ampelas; G Pomier-Layrargues; P M Huet; D Marleau
Journal:  Hepatology       Date:  1986 Sep-Oct       Impact factor: 17.425

10.  Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease.

Authors:  J F Schneider; A L Baker; N W Haines; G Hatfield; J L Boyer
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

View more
  3 in total

1.  Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test.

Authors:  Maciej Malinowski; Maximilian Jara; Katja Lüttgert; James Orr; Johan Friso Lock; Eckart Schott; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2014-07-04       Impact factor: 3.199

Review 2.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

3.  Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis.

Authors:  Tomasz Dziodzio; Robert Öllinger; Wenzel Schöning; Antonia Rothkäppel; Radoslav Nikolov; Andrzej Juraszek; Paul V Ritschl; Martin Stockmann; Johann Pratschke; Maximilian Jara
Journal:  BMC Gastroenterol       Date:  2020-08-12       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.